2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lods, N. Articles by Marti, H.-P. Search for Related Content PubMed PubMed Citation Articles by Lods, N. Articles by Marti, H.-P.

Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis

Nadège Lods^*, Paolo Ferrari^*, Felix J. Frey^*, Andreas Kappeler, Celine Berthier^*, Bruno Vogt^* and Hans-Peter Marti^*

*Division of Nephrology and Hypertension, Inselspital Bern, Bern, Switzerland; and Institute of Pathology, University of Bern, Bern, Switzerland

Correspondence to Dr. Hans-Peter Marti, Division of Nephrology/Hypertension, University of Bern, Inselspital Bern, CH-3010, Bern, Switzerland. Phone: 031-632-31-44; Fax: 031-632-94-44;

ABSTRACT. Equivalent long-term effects on the kidney are attributed to angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB). Nevertheless, it is unknown to which degree effects of these compounds on individual inflammatory mediators, including matrix metalloproteinases (MMP), are comparable. On the basis of structural and functional differences, it was hypothesized that ACEI and ARB differentially regulate MMP activity. In a randomized, prospective crossover trial, the effect of an ACEI (fosinopril; 20 mg/d) and of an ARB (irbesartan; 150 mg/d) on MMP activity was evaluated. Ten hypertensive patients with glomerulonephritis and normal or mildly reduced creatinine clearance were studied. MMP activity and tissue inhibitors of metalloproteinase (TIMP) levels were analyzed in serum and urine: without therapy, with ACEI, with ARB, and with both agents combined. Treatment periods continued for 6 wk separated by periods of 4 wk each without therapy. Untreated patients with glomerulonephritis displayed distinctively higher serum levels of MMP-2 but much lower MMP-1/-8/-9 concentrations compared with healthy control subjects. Immunohistology of MMP-2 and MMP-9 in kidney biopsy specimen was accordingly. However, these patients excreted higher amounts of MMP-2 and MMP-9 in urine than healthy control subjects, possibly reflecting ongoing glomerular inflammation. In patients with glomerulonephritis, ACEI significantly reduced overall MMP serum activity to 25%, whereas ARB did not show any effect. Activities of MMP-1/-2/-8/-9 were also significantly inhibited by fosinopril but not by irbesartan. Levels of TIMP-1/-2 remained unaffected. In conclusion, ACEI and ARB differentially regulate MMP activity, which may ultimately have consequences in certain types of MMP-dependent glomerulonephritis. E-mail: hpmarti@bluewin.ch

This article has been cited by other articles:

				L. Sanchez de Miguel, S. Neysari, S. Jakob, M. Petrimpol, N. Butz, A. Banfi, C. E. Zaugg, R. Humar, and E. J. Battegay B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart Cardiovasc Res, October 1, 2008; 80(1): 106 - 113. [Abstract] [Full Text] [PDF]

				J.-S. F. Sanders, M. G. Huitema, R. Hanemaaijer, H. van Goor, C. G. M. Kallenberg, and C. A. Stegeman Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1927 - F1934. [Abstract] [Full Text] [PDF]

				B. Bauvois, N. Mothu, J. Nguyen, T. Nguyen-Khoa, L.-H. Noel, and P. Jungers Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-{beta}1 in patients with distinct types of primary glomerulonephritis Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1115 - 1122. [Abstract] [Full Text] [PDF]

				J. Bolbrinker, S. Markovic, M. Wehland, W. B. W. H. Melenhorst, H. van Goor, and R. Kreutz Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 8 - 16. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673